毛片免费毛片一级jjj毛片,日本在线亚州精品视频在线,国产精品国偷自产在线,久久精品色,日韩精品免费电影,欧美综合国产精品日韩一,国产六区

首頁 /藥靶模型 /激酶靶點 /ROS1 /SLC34A2-ROS1/BaF3

SLC34A2-ROS1/BaF3

CBP73191

詢 價
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫

I. Introduction
Cell Line Name: SLC34A2-ROS1/BaF3
Host Cell: Ba/F3
Stability: 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application: Anti-proliferation assay and PD assay
Freeze Medium: 90% FBS+10% DMSO
Complete Culture Medium: RPMI-1640+10%FBS
Mycoplasma Status: Negative
 
II. Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).
In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).?
Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.
ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).

 
III. Representative Data

1. WB of SLC34A2-ROS1 expression

 

2.Sanger Sequencing of SLC34A2-ROS1 Fusion

2. Anti-proliferation assay

Figure 3. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1/BaF3 Stable Cell Line.


客服

微信

掃一掃,添加二維碼

電話

留言

藥靶模型聯(lián)系方式: 華東銷售經(jīng)理(上海):18240630236 華東銷售經(jīng)理(上海、江蘇、安徽):15715191010 華中&華西銷售經(jīng)理:18071545918 華中&西南銷售經(jīng)理:13871580511 華北銷售經(jīng)理:18628311252 全國銷售經(jīng)理:13816461235
診斷標(biāo)準(zhǔn)品聯(lián)系方式: 華東銷售經(jīng)理:15000320447 華北銷售經(jīng)理:18628311252 華中&華西銷售經(jīng)理:18071545918 華中&西南銷售經(jīng)理:13871580511 全國銷售經(jīng)理:13816461235

掃二維碼

立即提交
漯河市| 平遥县| 伊川县| 吉安县| 汾阳市| 黄山市| 望奎县| 永嘉县| 阿巴嘎旗| 石泉县| 宜兴市| 永善县| 孟津县| 新田县| 太湖县| 德令哈市| 阜城县| 寿阳县| 蓝田县| 遂宁市| 苏尼特左旗| 仁怀市| 永泰县| 衡山县| 长葛市| 通榆县| 大新县| 南部县| 卫辉市| 青田县| 涞源县| 商南县| 龙泉市| 兴隆县| 蒲江县| 富民县| 龙陵县| 获嘉县| 广宁县| 鹰潭市| 南丰县|